Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet
Retracted coronavirus (COVID-19) papers – Retraction Watch
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis - The Lancet Microbe
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression - The Lancet
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study - The Lancet
Elsevier: Preprints With The Lancet Launches on SSRN
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis - The Lancet Global Health
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - The Lancet Infectious Diseases
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room - The Lancet Microbe
For Authors: Submit your work
The Lancet on X: "NEW—Most reliable estimates to date suggest 1 in 8 COVID-19 patients develop #longCOVID symptoms. https://t.co/wechj5flvg https://t.co/pT8lBAWS4g" / X
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system - The Lancet Infectious Diseases
Congrats to Dr. Therriault and team on their amazing preprint in The Lancet! 👏 🧠 | ALZpath Inc. posted on the topic | LinkedIn
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas
Collaborative Research: Community Health Impact Coalition Lancet Preprint - Research - Community Health Toolkit
An interactive website tracking COVID-19 vaccine development - The Lancet Global Health
eBioMedicine Home Page
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study - The Lancet Public Health
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil - The Lancet
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet
Preprints with The Lancet: joining online research discussion platforms - The Lancet
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study - eBioMedicine
